Schaeffer's Top Stock Picks for '25

Stocks On the Move: Biogen Inc, AveXis Inc, and Amphastar Pharmaceuticals Inc

Biotech stocks Biogen Inc (BIIB), AveXis Inc (AVXS), and Amphastar Pharmaceuticals Inc (AMPH) are among the stocks making big moves in today's trading

Dec 27, 2016 at 2:45 PM
facebook X logo linkedin


U.S. stocks are higher, as tech stocks and homebuilders lead. Among specific equities in focus today are biotech stocks Biogen Inc (NASDAQ:BIIB), AveXis Inc (NASDAQ:AVXS), and Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Here's a quick look at what's moving BIIB, AVXS, and AMPH.

  • BIIB is up 1.4% at $291.42, after the U.S. Food and Drug Administration (FDA) granted approval for its spinal muscular atrophy drug, nusinersen, developed in partnership with Ionis Pharmaceuticals Inc (NASDAQ:IONS). BIIB is up more than 30% since its late-June lows, though the shares still sit below the key $300 level. Option bulls have been betting on more upside, with Biogen Inc's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) of 2.20 sitting in the 84th percentile of its annual range.

  • AVXS is down 6.4% at $49.90, after BIIB's FDA approval. AveXis Inc is currently developing a similar drug, AVXS-101, which would now be the second spinal muscular atrophy drug available on the market, if approved. However, one Chardan analyst thinks AVXS-101 could still clear space in the market, given its lower death rate, which gives it the potential to be a "breakthrough therapy." The Wall Street rookie has tumbled nearly 32% since hitting an all-time peak last month, and short sellers have been piling on. Short interest on AVXS surged 171.95% during the past two reporting periods, and now accounts for 20% of the stock's total available float.
  • AMPH is among the worst performers on the Nasdaq, currently trading 9.2% lower at $18.56, on news that the FDA has issued a Complete Response Letter (CRL) denying the biotech's New Drug Application (NDA) (subscription required) for its primatene mist asthma inhaler. Amphastar Pharmaceuticals Inc's CEO said the company will work to address the FDA's concerns by the middle of 2017. AMPH is still up more than 75% since its early March lows, though the shares now sit below the $19.50 level that has acted as support since a mid-November bull gap. Short sellers are likely cheering today's move, with AMPH's 2.7 million shorted shares accounting for more than 7.4% of AMPH's float, which would take just under two weeks of trading to cover, at the stocks' average daily volume.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter